NR1H4 and metabolic dysfunction-associated steatohepatitis: Numerous clinical studies have demonstrated that OCA (a FXR agonist) has a significant therapeutic effect on NASH by increasing insulin sensitivity and reducing markers of liver inflammation and fibrosis (Mudaliar et al., 2013; Neuschwander-Tetri et al., 2015; Younossi et al., 2019).